SCHEDULE: Vanguard Group Reduces Stake in Shattuck Labs to Below 5%

The Vanguard Group has filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 4.48% in Shattuck Labs Inc.'s common stock.

Summary

• The Vanguard Group reported beneficial ownership of 2,148,174 shares of Shattuck Labs Inc. common stock.
• This represents 4.48% of the class of securities, a decrease from a previously held stake that was likely above 5% given this is an amendment to a Schedule 13G filing.
• Vanguard holds sole dispositive power over 2,133,317 shares and shared dispositive power over 14,857 shares.
• Vanguard holds no sole or shared voting power over these shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a change in their previously reported beneficial ownership.

Sentiment

Score: 5

Explanation: The filing itself is a factual disclosure of ownership, which is neutral. However, the implied reduction in a major institutional stake could be interpreted as a slightly negative signal for the company's stock, leading to a neutral-to-slightly-negative overall sentiment.

Negatives

• The reduction in The Vanguard Group's beneficial ownership to below 5% may signal a decrease in institutional confidence or a portfolio rebalancing by a major investor.

Future Outlook

NA

Management Comments

• The Vanguard Group certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing reflects a change in a major institutional investor's stake in Shattuck Labs, a biotechnology company. Such changes can be part of broader portfolio adjustments within the healthcare or biotech sectors, or specific to the investor's view on the company's prospects.

Stakeholder Impact

• Shareholders: The reduction in a major institutional investor's stake could influence investor sentiment and potentially the company's stock price.

Key Dates

Keywords

Shattuck Labs, Vanguard Group, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals